参考文献
［1］ Siegel RL，Miller KD，Jemal A.Cancer statistics（2017）［J］.CA Cancer J Clin，2017，67（1）：7-30.
［2］ Siegel RL，Miller KD，Jemal A.Cancer statistics（2016）［J］.CA Cancer J Clin，2016，66（1）：7-30.
［3］ Gillen S，Schuster T，Meyer Zum Büschenfelde C，et al.Preoperative／neoadjuvant therapy in pancreatic cancer：a systematic review and meta-analysis of response and resection percentages［J］.PLoS Med，2010，7（4）：e1000267.
［4］ Siegel R，Ma J，Zou Z，et al.Cancer statistics（2014）［J］.CA Cancer J Clin，2014，64（2）：9-29.
［5］ Chen W，Zheng R，Baade PD，et al.Cancer statistics in China（2015）［J］.CA Cancer J Clin，2016，66（2）：115-132.
［6］ Maisonneuve P，Lowenfels AB.Risk factors for pancreatic cancer：a summary review of metaanalytical studies［J］.Int J Epidemiol，2015，44（1）：186-198.
［7］ Genkinger JM，Kitahara CM，Bernstein L，et al.Central adiposity，obesity during early adulthood，and pancreatic cancer mortality in a pooled analysis of cohort studies［J］.Ann Oncol，2015，26（11）：2257-2266.
［8］ Larsson SC，Wolk A.Red and processed meat consumption and risk of pancreatic cancer：meta-analysis of prospective studies［J］.Br J Cancer，2012，106（3）：603-607.
［9］ Rohrmann S，Linseisen J，Nöthlings U，et al.Meat and fish consumption and risk of pancreatic cancer：results from the European Prospective Investigation into cancer and nutrition［J］.Int J Cancer，2013，132（3）：617-624.
［10］ Bosetti C，Bravi F，Turati F，et al.Nutrient-based dietary patterns and pancreatic cancer risk［J］.Ann Epidemiol，2013，23（3）：124-128.
［11］ Tramacere I，Scotti L，Jenab M，et al.Alcohol drinking and pancreatic cancer risk：a meta-analysis of the dose-risk relation［J］.Int J Cancer，2010，126（6）：1474-1486.
［12］ Lucenteforte E，La Vecchia C，Silverman D，et al.Alcohol consumption and pancreatic cancer：a pooled analysis in the International Pancreatic Cancer Case-Control Consortium（PanC4）［J］.Ann Oncol，2012，23（2）：374-382.
［13］ Bosetti C，Rosato V，Li D，et al.Diabetes，antidiabetic medications，and pancreatic cancer risk：an analysis from the International Pancreatic Cancer Case-Control Consortium［J］.Ann Oncol，2014，25（10）：2065-2072.
［14］ Hruban RH，Canto MI，Goggins M，et al.Update on familial pancreatic cancer［J］.Adv Surg，2010，44（1）：293-311.
［15］ Kleeff J，Korc M，Apte M，et al.Pancreatic cancer［J］.Nat Rev Dis Primers，2016，2（5）：16-22.
［16］ Neoptolemos JP，Stocken DD，Friess H，et al.A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer［J］.N Eng J Med，2004，350（12）：1200-1210.
［17］ Oettle H，Post S，Neuhaus P，et al.Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer：a randomized controlled trial［J］.JAMA，2007，297（3）：267-277.
［18］ Oettle H，Neuhaus P，Hochhaus A，et al.Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer：the CONKO-001randomized trial［J］.JAMA，2013，310（14）：1473-1481.
［19］ Neoptolemos JP，Stocken DD，Bassi C，et al.Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection：a randomized controlled trial［J］.JAMA，2010，304（10）：1073-1081.
［20］ Neoptolemos JP，Palmer DH，Ghaneh P，et al.Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer（ESPAC-4）：a multicentre，open-label，randomised，phase 3trial［J］.Lancet，2017，389（10073）：1011-1024.
［21］ Maeda A，Boku N，Fukutomi A，et al.Randomized phaseⅢtrial of adjuvant chemotherapy with gemcitabine versus S-1in patients with resected pancreatic cancer：Japan Adjuvant Study Group of Pancreatic Cancer（JASPAC-01）［J］.Jpn J Clin Oncol，2008，38（3）：227-229.
［22］ Sudo K，Nakamura K，Yamaguchi T.S-1in the treatment of pancreatic cancer［J］.World J Gastroenterol，2014，20（41）：15110-15118.
［23］ Conroy T，Desseigne F，Ychou M，et al.FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer［J］.N Engl J Med，2011，364（19）：1817-1825.
［24］ Von Hoff DD，Ervin T，Arena FP，et al.Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine［J］.N Engl J Med，2013，369（18）：1691-1703.
［25］ Chauffert B，Mornex F，Bonnetain F，et al.PhaseⅢtrial comparing intensive induction chemoradiotherapy（60Gy，infusional 5-FU and intermittent cisplatin）followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer.Definitive results of the 2000-01FFCD／SFRO study［J］.Ann Oncol，2008，19（9）：1592-1599.
［26］ Loehrer PJ Sr，Feng Y，Cardenes H，et al.Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer：an Eastern Cooperative Oncology Group trial［J］.J Clin Oncol，2011，29（31）：4105-4112.
［27］ Huguet F，Girard N，Guerche CS，et al.Chemoradiotherapy in the management of locally advanced pancreatic carcinoma：aqualitative systematic review［J］.J Clin Oncol，2009，27（13）：2269-2277.
［28］ Herman JM，Chang DT，Goodman KA，et al.PhaseⅡmulti-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma［J］.Cancer，2015，121（7）：1128-1137.
［29］ Schellenberg D，Goodman KA，Lee F，et al.Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer［J］.Int J Radiat Oncol Biol Phys，2008，72（3）：678-686.
［30］ Schellenberg D，Kim J，Christman-Skieller C，et al.Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer［J］.Int J Radiat Oncol Biol Phys，2011，81（1）：181-188.
［31］ Koong AC，Le QT，Ho A，et al.PhaseⅠstudy of stereotactic radiosurgery in patients with locally advanced pancreatic cancer［J］.Int J Radiat Oncol Biol Phys，2004，58（4）：1017-1021.
［32］ Chang DT，Schellenberg D，Shen J，et al.Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas［J］.Cancer，2009，115（1）：665-672.
［33］ Koong AC，Christofferson E，Le QT，et al.PhaseⅡstudy to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer［J］.Int J Radiat Oncol Biol Phys，2005，63（2）：320-323.
［34］ Kim SS，Nakakura EK，Wang ZJ，et al.Preoperative FOLFIRINOX for borderline resectable pancreatic cancer：Is radiation necessary in the modern era of chemotherapy？［J］.J Surg Oncol，2016，114（5）：587-596.
［35］ McClaine RJ，Lowy AM，Sussman JJ，et al.Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer［J］.HPB（Oxford），2010，12（1）：73-79.
［36］ Paniccia A，Edil BH，Schulick RD，et al.Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma：a retrospective cohort study［J］.Medicine（Baltimore），2014，93（27）：e198.
［37］ Rose JB，Rocha FG，Alseidi A，et al.Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival［J］.Ann Surg Oncol，2014，21（5）：1530-1537.
［38］ Breslin TM，Hess KR，Harbison DB，et al.Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas：treatment variables and survival duration［J］.Ann Surg Oncol，2001，8（2）：123-132.
［39］ Greer SE，Pipas JM，Sutton JE，et al.Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma［J］.J Am Coll Surg，2008，206（3）：451-457.
［40］ Takahashi H，Akita H，Tomokuni A，et al.Preoperative gemcitabine-based chemoradiation therapy for borderline resectable pancreatic cancer：impact of venous and arterial involvement status on surgical and pattern of recurrence［J］.Ann Surg，2016，264（15）：1091-1097.
［41］ Chuong MD，Springett GM，Freilich JM，et al.Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated［J］.Int J Radiat Oncol Biol Phys，2013，86（3）：516-522.
［42］ Mellon EA，Hoffe SE，Springett GM，et al.Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma［J］.Acta Oncol，2015，54（7）：979-985.
［43］ Moningi S，Dholakia AS，Raman SP，et al.The role of stereotactic body radiation therapy for pancreatic cancer：a single-institution experience［J］.Ann Surg Oncol，2015，22（7）：2352-2358.
［44］ Tempero MA，Malafa MP，Al-Hawary M，et al.Pancreatic adenocarcinoma（version 2）［J］.J Natl Compr Canc Netw，2017，15（8）：1028-1061.
［45］ Balaban EP，Mangu PB，Khorana AA，et al.Locally advanced，unresectable pancreatic cancer：american society of clinical oncology clinical practice guideline［J］.J Clin Oncol，2016，34（22）：2654-2668.
［46］ Small W，Hayes JP，Suh WW，et al.ACR appropriateness criteria®borderline and unresectable pancreas cancer［J］.Oncology（Williston Park），2016，30（7）：619-624，627，632.
［47］ Goldberg SN，Mallery S，Gazelle GS，et al.EUS-guided radiofrequency ablation in the pancreas：results in a porcine model［J］.Gastrointest Endosc，1999，50（3）：392-401.
［48］ Keane MG，Bramis K，Pereira SP，et al.Systematic review of novel ablative methods in locally advanced pancreatic cancer［J］.World J Gastroenterol，2014，20（9）：2267-2278.
［49］ Paiella S，Salvia R，Ramera M，et al.Local ablative strategies for ductal pancreatic cancer（radiofrequency ablation，irreversible electroporation）：a review［J］.Gastroenterol Res Pract，2016（1）：1-10.
［50］ Girelli R，Frigerio I，Giardino A，et al.Results of 100pancreatic radiofrequency ablations in the context of a multimodal strategy for stageⅢductal adenocarcinoma［J］.Langenbecks Arch Surg，2013，398（1）：63-69.
［51］ Chadha AS，Khoo A，Aliru ML，et al.Recent advances and prospects for multimodality therapy in pancreatic cancer［J］.Semin Radiat Oncol，2016，26（4）：320-337.
［52］ Frese KK，Neesse A，Cook N，et al.Nab-paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer［J］.Cancer Discov，2012，2（3）：260-269.
［53］ Arsawang U，Saengsawang O，Rungrotmongkol T，et al.How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system？［J］.J Mol Graph Model，2011，29（5）：591-596.
［54］ Stacey M，Osgood C，Kalluri BS，et al.Nanosecond pulse electrical fields used in conjunction with multi-wall carbon nanotubes as a potential tumor treatment［J］.Biomed Mater，2011，6（1）：011002.
［55］ Patra CR，Bhattacharya R，Wang E，et al.Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent［J］.Cancer Res，2008，68（6）：1970-1978.
［56］ Kudgus RA，Szabolcs A，Khan JA，et al.Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics［J］.PLoS One，2013，8（3）：e57522.
［57］ Meng H，Wang M，Liu H，et al.Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice［J］.ACS Nano，2015，9（4）：3540-3557.
［58］ Ko AH，Tempero MA，Shan YS，et al.A multinational phaseⅡstudy of nanoliposomal irinotecan sucrosofate（PEP02，MM-398）for patients with gemcitabine-refractory metastatic pancreatic cancer［J］.Br J Cancer，2013，109（4）：920-925.
［59］ Ur Rehman SS，Lim K，Wang-Gillam A.Nanoliposomal irinotecan plus fluorouracil and folinic acid：a new treatment option in metastatic pancreatic cancer［J］.Expert Rev Anticancer Ther，2016，16（1）：485-492.
［60］ Yi SY，Park YS，Kim HS，et al.Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer［J］.Cancer Chemother Pharmacol，2009，63（6）：1141-1145.
［61］ Rosati LM，Kumar R，Herman JM.Integration of stereotactic body radiation therapy into the multidisciplinary management of pancreatic cancer［J］.Semin Radiat Oncol，2017，27（3）：256-267.
［62］ Hainfeld JF，Dilmanian FA，Slatkin DN，et al.Radiotherapy enhancement with gold nanoparticles［J］.J Pharm Pharmacol，2008，60（8）：977-985.
［63］ Schuemann J，Berbeco R，Chithrani DB，et al.Roadmap to clinical use of gold nanoparticles for radiation sensitization［J］.Int J Radiat Oncol Biol Phys，2016，94（1）：189-205.
［64］ Chatterjee DK，Wolfe T，Lee J，et al.Convergence of nanotechnology with radiation therapy-insights and implications for clinical translation［J］.Transl Cancer Res，2013，2（4）：256-268.
［65］ Hainfeld JF，Slatkin DN，Smilowitz HM.The use of gold nanoparticles to enhance radiotherapy in mice［J］.Phys Med Biol，2004，49（18）：309-315.
［66］ Kunjachan S，Detappe A，Kumar R，et al.Nanoparticle mediated tumor vascular disruption：a vovel strategy in radiation therapy［J］.Nano Lett，2015，15（11）：7488-7496.
［67］ Demaria S，Ng B，Devitt ML，et al.Ionizing radiation inhibition of distant untreated tumors（abscopal effect）is immune mediated［J］.Int J Radiat Oncol Biol Phys，2004，58（3）：862-870.
［68］ Demaria S，Bhardwaj N，McBride WH，et al.Combining radiotherapy and immunotherapy：a revived partnership［J］.Int J Radiat Oncol Biol Phys，2005，63（3）：655-666.
［69］ Lugade AA，Moran JP，Gerber SA，et al.Local radiation therapy of B16melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor［J］.J Immunol，2005，174（12）：7516-7523.
［70］ Zhang B，Bowerman NA，Salama JK，et al.Induced sensitization of tumor stroma leads to eradication of established cancer by T cells［J］.J Exp Med，2007，204（1）：49-55.
［71］ Lee Y，Auh SL，Wang Y，et al.Therapeutic effects of ablative radiation on local tumor require CD8+T cells：changing strategies for cancer treatment［J］.Blood，2009，114（3）：589-595.
［72］ Burnette B，Fu YX，Weichselbaum RR.The confluence of radiotherapy and immunotherapy［J］.Front Oncol，2012（2）：143.
［73］ Frey B，Rubner Y，Wunderlich R，et al.Induction of abscopal anti-tumor immunity and immunogenic tumor cell death by ionizing irradiation—implications for cancer therapies［J］.Curr Med Chem，2012，19（12）：1751-1764.
［74］ Formenti SC，Demaria S.Combining radiotherapy and cancer immunotherapy：aparadigm shift［J］.J Natl Cancer Inst，2013，105（4）：256-265.
［75］ Burnette B，Weichselbaum RR.Radiation as an immune modulator［J］.Semin Radiat Oncol，2013，23（4）：273-280.
［76］ Demaria S，Formenti SC.Radiotherapy effects on anti-tumor immunity：implications for cancer treatment［J］.Front Oncol，2013（3）：128.
［77］ Deng L，Liang H，Burnette B，et al.Irradiation and anti-PD-L1treatment synergistically promote antitumor immunity in mice［J］.J Clin Invest，2014，124（2）：687-695.
［78］ Lim JY，Gerber SA，Murphy SP，et al.TypeⅠinterferons induced by radiation therapy mediate recruitment and effector function of CD8+T cells［J］.Cancer Immunol Immunother，2014，63（3）：259-271.
［79］ Sharabi AB，Nirschl CJ，Kochel CM，et al.Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen［J］.Cancer Immunol Res，2015，3（4）：345-355.
［80］ Sharabi AB，Tran PT，Lim M，et al.Stereotactic radiation therapy combined with immunotherapy：augmenting the role of radiation in local and systemic treatment［J］.Oncology（Williston Park），2015，29（5）：331-340.
［81］ Golden EB，Chhabra A，Chachoua A，et al.Local radiotherapy and granulocyte-macrophage colonystimulating factor to generate abscopal responses in patients with metastatic solid tumours：aproof-ofprinciple trial［J］.Lancet Oncol，2015，16（7）：795-803.
［82］ Park SS，Dong H，Liu X，et al.PD-1restrains radiotherapy-induced abscopal effect［J］.Cancer Immunol Res，2015，3（6）：610-619.
［83］ Vanpouille-Box C，Diamond JM，Pilones KA，et al.TGFβis a master regulator of radiation therapyinduced antitumor immunity［J］.Cancer Res，2015，75（11）：2232-2242.
［84］ Meng Y，Beckett MA，Liang H，et al.Blockade of tumor necrosis factor alpha signaling in tumorassociated macrophages as a radiosensitizing strategy［J］.Cancer Res，2010，70（4）：1534-1543.
［85］ Ahn GO，Tseng D，Liao CH，et al.Inhibition of Mac-1（CD11b／CD18）enhances tumor response to radiation by reducing myeloid cell recruitment［J］.Proc Natl Acad Sci U S A，2010，107（18）：8363-8368.
［86］ Chiang CS，Fu SY，Wang SC，et al.Irradiation promotes an M2macrophage phenotype in tumor hypoxia［J］.Front Oncol，2012（2）：89.
［87］ Schaue D，McBride WH.T lymphocytes and normal tissue responses to radiation［J］.Front Oncol，2012（2）：119.
［88］ Zitvogel L，Kroemer G.Subversion of anticancer immunosurveillance by radiotherapy［J］.Nat Immunol，2015，16（10）：1005-1007.
［89］ Joosten JJ，Muijen GN，Wobbes T，et al.In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth：an experimental study［J］.Cryobiology，2001，42（1）：49-58.
［90］ Mir LM，Rubinsky B.Treatment of cancer with cryochemotherapy［J］.Br J Cancer，2002，86（10）：1658-1660.
［91］ Homasson JP，Pecking A，Roden S，et al.Tumor fixation of bleomycin labeled with 57cobalt before and after cryotherapy of bronchial carcinoma［J］.Cryobiology，1992，29（5）：543-548.
［92］ Chiu D，Niu L，Mu F，et al.The experimental study for efficacy and safety of pancreatic cryosurgery［J］.Cryobiology，2010，60（3）：281-286.
［93］ Kovach SJ，Hendrickson RJ，Cappadona CR，et al.Cryoablation of unresectable pancreatic cancer［J］.Surgery，2002，131（4）：463-464.
［94］ Hoffmann NE，Bischof JC.The cryobiology of cryosurgical injury［J］.Urology，2002，60（2Suppl 1）：40-49.
［95］ Lagerveld BW，van Horssen P，Pes MP，et al.Immediate effect of kidney cryoablation on renal arterial structure in a porcine model studied by imaging cryomicrotome［J］.J Urol，2010，183（2）：1221-1226.
［96］ Perez-Johnston R，Lenhart DK，Sahani DV.CT angiography of the hepatic and pancreatic circulation［J］.Radiol Clin North Am，2010，48（2）：311-330.
［97］ Lillemoe KD，Cameron JL，Yeo CJ，et al.Pancreaticoduodenectomy.Does it have a role in the palliation of pancreatic cancer？［J］.Ann Surg，1996，223（6）：718-728.
［98］ Sabel MS.Cryo-immunology：a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses［J］.Cryobiology，2009，58（1）：1-11.
［99］ Chu KF，Dupuy DE.Thermal ablation of tumours：biological mechanisms and advances in therapy［J］.Nat Rev Cancer，2014，14（3）：199-208.
［100］ Zerbini A，Pilli M，Penna A，et al.Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses［J］.Cancer Res，2006，66（2）：1139-1146.
［101］ Schueller G，Kettenbach J，Sedivy R，et al.Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model［J］.Oncol Rep，2004，12（1）：495-499.
［102］ Teng LS，Jin KT，Han N，et al.Radiofrequency ablation，heat shock protein 70and potential antitumor immunity in hepatic and pancreatic cancers：a minireview［J］.Hepat Pancreat Dis Int，2010，9（4）：361-365.
［103］ Rai R，Richardson C，Flecknell P，et al.Study of apoptosis and heat shock protein（HSP）expression in hepatocytes following radiofrequency ablation（RFA）［J］.J Surg Res，2005，129（1）：147-151.(https://www.daowen.com)
［104］ Liu Q，Zhai B，Yang W，et al.Abrogation of local cancer recurrence after radiofrequency ablation by dendritic cell-based hyperthermic tumor vaccine［J］.Mol Ther J Am Soc Gene Ther，2009，17（12）：2049-2057.
［105］ den Brok MH，Sutmuller RP，Nierkens S，et al.Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces antitumour immunity［J］.Br J Cancer，2006，95（7）：896-905.
［106］ Rovere-Querini P，Manfredi AA.Tumor destruction and in situ delivery of antigen presenting cells promote antineoplastic immune responses：implications for the immunotherapy of pancreatic cancer［J］.JOP，2004，5（4）：308-314.
［107］ Dallal RM，Christakos P，Lee K，et al.Paucity of dendritic cells in pancreatic cancer［J］.Surgery，2002，131（2）：135-138.
［108］ Napoletano C，Taurino F，Biffoni M，et al.RFA strongly modulates the immune system and antitumor immune responses in metastatic liver patients［J］.Int J Oncol，2008，32（2）：481-490.
［109］ Fietta AM，Morosini M，Passadore I，et al.Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer［J］.Hum Immunol，2009，70（7）：477-486.
［110］ Zerbini A，Pilli M，Laccabue D，et al.Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response［J］.Gastroenterology，2010，138（5）：1931-1942.
［111］ Hansler J，Wissniowski TT，Schuppan D，et al.Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases［J］.World J Gastroenterol，2006，12（23）：3716-3721.
［112］ Carrara S，Petrone MC，Testoni PA，et al.Tumors and new endoscopic ultrasound-guided therapies［J］.World J Gastrointest Endosc，2013，5（4）：141-147.
［113］ Wright AS，Sampson LA，Warner TF，et al.Radiofrequency versus microwave ablation in a hepatic porcine model［J］.Radiology，2005，236（1）：132-139.
［114］ Kim J.Endoscopic ultrasound-guided treatment of pancreatic cystic and solid masses［J］.Clin Endosc，2015，48（4）：308-311.
［115］ Ansari D，Kristoffersson S，Andersson R，et al.The role of irreversible electroporation（IRE）for locally advanced pancreatic cancer：a systematic review of safety and efficacy［J］.Scand J Gastroenterol，2017，52（11）：1165-1171.
［116］ Beger HG，Gansauge F，Buchler MW，et al.Intraarterial adjuvant chemotherapy after pancreaticoduodenectomy for pancreatic cancer：significant reduction in occurrence of liver metastasis［J］.World J Surg，1999，23（9）：946-949.
［117］ Beger HG，Link KH，Gansauge F.Adjuvant regional chemotherapy in advanced pancreatic cancer：results of a prospective study［J］.Hepatogastroenterology，1998，45（21）：638-643.
［118］ Morak MJ，van der Gaast A，Incrocci L，et al.Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer：aprospective randomized controlled trial［J］.Ann Surg，2008，248（6）：1031-1041.
［119］ Aiura K，Takahashi S，Matsui J，et al.Beneficial effects of 5-Fluorouracil and heparin-based portal infusion chemotherapy combined with mitomycin C and cisplatin after curative resection of pancreatic cancer［J］.Pancreatology，2010，10（2）：250-258.
［120］ Chen Y，Wang XL，Wang JH，et al.Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer［J］.Anticancer Drugs，2014，25（1）：958-963.
［121］ Tanaka T，Sho M，Nishiofuku H，et al.Unresectable pancreatic cancer：arterial embolization to achieve a single blood supply for intra-arterial infusion of 5-fluorouracil and full-dose IV gemcitabine［J］.AJR Am J Roentgenol，2012，198（1）：1445-1452.
［122］ Ni XG，Bai XF，Mao YL，et al.The clinical value of serum CEA，CA19-9，and CA242in the diagnosis and prognosis of pancreatic cancer［J］.Eur J Surg Oncol，2005，31（2）：164-169.
［123］ Safi F，Schlosser W，Kolb G，et al.Diagnostic value of CA19-9in patients with pancreatic cancer and nonspecifi c gastrointestinal symptoms［J］.J Gastrointest Surg，1997，1（2）：106-112.
［124］ Goonetilleke KS，Siriwardena AK.Systematic review of carbohydrate antigen（CA19-9）as a biochemical marker in the diagnosis of pancreatic cancer［J］.Eur J Surg Oncol，2007，33（3）：266-270.
［125］ Gattani AM，Mandeli J，Bruckner HW.Tumor markers in patients with pancreatic carcinoma［J］.Cancer，1996，78（1）：57-62.
［126］ Chan A，Prassas I，Dimitromanolakis A，et al.Validation of biomarkers that complement CA19.9in detecting early pancreatic cancer［J］.Clin Cancer Res，2014，20（22）：5787-5795.
［127］ O'Brien DP，Sandanayake NS，Jenkinson C，et al.Serum CA19-9is significantly upregulated up to 2 years before diagnosis with pancreatic cancer：implications for early disease detection［J］.Clin Cancer Res，2015，21（3）：622-631.
［128］ Ahn SS，Kim MJ，Choi JY，et al.Indicative findings of pancreatic cancer in prediagnostic CT［J］.Eur Radiol，2009，19（10）：2448-2455.
［129］ Diehl SJ，Lehmann KJ，Sadick M，et al.Pancreatic cancer：value of dual-phase helical CT in assessing resectability［J］.Radiology，1998，206（2）：373-378.
［130］ Lu DS，Reber HA，Krasny RM，et al.Local staging of pancreatic cancer：criteria for unresectability of major vessels as revealed by pancreatic-phase，thin-section helical CT［J］.AJR Am J Roentgenol，1997，168（6）：1439-1443.
［131］ Wang Z，Chen JQ，Liu JL，et al.FDG-PET in diagnosis，staging and prognosis of pancreatic carcinoma：a meta-analysis［J］.World J Gastroenterol，2013，19（29）：4808-4817.
［132］ Rijkers AP，Valkema R，Duivenvoorden HJ，et al.Usefulness of F-18-fluorodeoxyglucose positron emission tomography to confirm suspected pancreatic cancer：a meta-analysis［J］.Eur J Surg Oncol，2014，40（7）：794-804.
［133］ Tang S，Huang G，Liu J，et al.Usefulness of 18F-FDG PET，combined FDG-PET／CT and EUS in diagnosing primary pancreatic carcinoma：a meta-analysis［J］.Eur J Radiol，2011，78（1）：142-150.
［134］ Kamisawa T，Wood LD，Itoi T，et al.Pancreatic cancer［J］.Lancet，2016，388（2）：73-85.
［135］ Park HS，Lee JM，Choi HK，et al.Preoperative evaluation of pancreatic cancer：comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT［J］.J Magn Reson Imaging，2009，30（3）：586-595.
［136］ Fattahi R，Balci NC，Perman WH，et al.Pancreatic diffusion-weighted imaging（DWI）：comparison between mass-forming focal pancreatitis（FP），pancreatic cancer（PC），and normal pancreas［J］.J Magn Reson Imaging，2009，29（2）：350-356.
［137］ Takeuchi M，Matsuzaki K，Kubo H，et al.High-b-value diffusion-weighted magnetic resonance imaging of pancreatic cancer and mass-forming chronic pancreatitis：preliminary results［J］.Acta Radiol，2008，49（1）：383-386.
［138］ Sandrasegaran K，Nutakki K，Tahir B，et al.Use of diffusion-weighted MRI to differentiate chronic pancreatitis from pancreatic cancer［J］.AJR Am J Roentgenol，2013，201（5）：1002-1008.
［139］ Maccioni F，Martinelli M，Al Ansari N，et al.Magnetic resonance cholangiography：past，present and future：a review［J］.Eur Rev Med Pharmacol Sci，2010，14（8）：721-725.
［140］ Agarwal B，Abu-Hamda E，Molke KL，et al.Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer［J］.Am J Gastroenterol，2004，99（5）：844-850.
［141］ DeWitt J，Devereaux B，Chriswell M，et al.Comparison of endoscopic ultrasonography and multidetector computed tomography for detecting and staging pancreatic cancer［J］.Ann Intern Med，2004，141（10）：753-763.
［142］ Gong TT，Hu DM，Zhu Q.Contrast-enhanced EUS for differential diagnosis of pancreatic mass lesions：a meta-analysis［J］.Gastrointest Endosc，2012，76（2）：301-309.
［143］ Bang JY，Magee SH，Ramesh J，et al.Randomized trial comparing fanning with standard technique for endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic mass lesions［J］.Endoscopy，2013，45（06）：445-450.
［144］ Nakai Y，Isayama H，Chang KJ，et al.Slow pull versus suction in endoscopic ultrasound-guided fi neneedle aspiration of pancreatic solid masses［J］.Dig Dis Sci，2014，59（7）：1578-1585.
［145］ Attam R，Arain MA，Bloechl SJ，et al.“Wet suction technique（WEST）”：a novel way to enhance the quality of EUS-FNA aspirate.Results of a prospective，single-blind，randomized，controlled trial using a 22-gauge needle for EUS-FNA of solid lesions［J］.Gastrointest Endosc，2015，81（6）：1401-1407.
［146］ Qin SY，Zhou Y，Li P，et al.Diagnostic efficacy of cell block immunohistochemistry，smear cytology，and liquid-based cytology in endoscopic ultrasound-guided fi ne-needle aspiration of pancreatic lesions：a single-institution experience［J］.PLoS One，2014，9（9）：e108762.
［147］ Brand RE，Adai AT，Centeno BA，et al.A microRNA-based test improves endoscopic ultrasound-guided cytologic diagnosis of pancreatic cancer［J］.Clin Gastroenterol Hepatol，2014，12（10）：1717-1723.
［148］ Jabbar KS，Verbeke C，Hyltander AG，et al.Proteomic mucin profiling for the identification of cystic precursors of pancreatic cancer［J］.J Natl Cancer Inst，2014，106（2）：djt439.
［149］ Fuccio L，Hassan C，Laterza L，et al.The role of K-ras gene mutation analysis in EUS-guided FNA cytology specimens for the differential diagnosis of pancreatic solid masses：a meta-analysis of prospective studies［J］.Gastrointest Endosc，2013，78（4）：596-608.
［150］ Kamisawa T，Imai M，Yui Chen P，et al.Strategy for differentiating autoimmune pancreatitis from pancreatic cancer［J］.Pancreas，2008，37（1）：e62-67.
［151］ Shimosegawa T，Chari ST，Frulloni L，et al.International consensus diagnostic criteria for autoimmune pancreatitis：guidelines of the International Association of Pancreatology［J］.Pancreas，2011，40（3）：352-358.
［152］ 倪泉兴，虞先濬，刘亮.中国胰腺癌临床诊断标准的探讨［J］.中国癌症杂志，2012，22（2）：81-87.
［153］ Xu K，Niu L，Yang D.Cryosurgery for pancreatic cancer［J］.Gland Surg，2013，2（1）：30-39.
［154］ Salhab M，Canelo R.An overview of evidence-based management of hepatocellular carcinoma：a metaanalysis［J］.J Cancer Res Ther，2011，7（1）：463-475.
［155］ Sweesy MW，Holland JL，Smith KW.Electromagnetic interference in cardiac rhythm management devices［J］.AACN Clin Issues，2004，15（3）：391-403.
［156］ Dunki-Jacobs EM，Philips P，Martin RC 2nd.Evaluation of resistance as a measure of successful tumor ablation during irreversible electroporation of the pancreas［J］.J Am Coll Surg，2014，218（2）：179-187.
［157］ Fegrachi S，Molenaar IQ，Klaessens JH，et al.Radiofrequency ablation of the pancreas with and without intraluminal duodenal cooling in a porcine model［J］.J Surg Res，2013，184（2）：867-872.
［158］ Martin RCG 2nd.Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation［J］.J Surg Oncol，2017，116（1）：35-45.
［159］ Tasu JP，Vesselle G，Herpe G，et al.Irreversible electroporation for locally advanced pancreatic cancer［J］.Diagn Interv Imaging，2016，97（12）：1297-1304.
［160］ Changela K，Patil R，Duddempudi S，et al.Endoscopic ultrasound-guided radiofrequency ablation of the pancreatic tumors：apromising tool in management of pancreatic tumors［J］.Can J Gastroenterol Hepatol，2016：4189358.
［161］ D'Onofrio M，Ciaravino V，De Robertis R，et al.Percutaneous ablation of pancreatic cancer［J］.World J Gastroenterol，2016，22（3）：9661-9673.
［162］ 赵庆孝，常兆华，李雷.肿瘤冷冻消融器械的发展现状［J］.介入放射学杂志，2009，18（07）：553-556.
［163］ 孙钢.不可逆电穿孔技术消融肿瘤研究进展［J］.介入放射学杂志，2015，24（04）：277-281.
［164］ Girelli R，Frigerio I，Salvia R，et al.Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer［J］.Br J Surg，2010，97（2）：220-225.
［165］ Date RS，McMahon RF，Siriwardena AK.Radiofrequency ablation of the pancreas I：definition of optimal thermal kinetic parameters and the effect of simulated portal venous circulation in an ex-vivo porcine model［J］.JOP，2005，6（6）：581-587.
［166］ He L，Niu L，Korpan NN，et al.Clinical practice guidelines for cryosurgery of pancreatic cancer：a consensus statement From the China Cooperative Group of Cryosurgery on Pancreatic Cancer，International Society of Cryosurgery，and Asian Society of Cryosurgery［J］.Pancreas，2017，46（8）：967-972.
［167］ Tasu JP，Vesselle G，Herpe G.Irreversible electroporation for locally advanced pancreatic cancer：where do we stand in 2017？［J］.Pancreas，2017，46（3）：283-287.
［168］ Dunki-Jacobs EM，Philips P，Martin RC.Evaluation of thermal injury to liver，pancreas and kidney during irreversible electroporation in an in vivo experimental model［J］.2nd.Br J Surg，2014，101（9）：1113-1121.
［169］ Hinshaw JL，Lubner MG，Ziemlewicz TJ，et al.Percutaneous tumor ablation tools：microwave，radiofrequency，or cryoablation—what should you use and why？［J］.Radiographics，2014，34（5）：1344-1362.
［170］ Wang Y，Sun Y，Feng L，et al.Internally cooled antenna for microwave ablation：results in ex vivo and in vivo porcine livers［J］.Eur J Radiol，2008，67（2）：357-361.
［171］ Brace CL.Dual-slot antennas for microwave tissue heating：parametric design analysis and experimental validation［J］.Med Phys，2011，38（2）：4232-4240.
［172］ Liang P，Yu J，Lu MD，et al.Practice guidelines for ultrasound-guided percutaneous microwave ablation for hepatic malignancy［J］.World J Gastroenterol，2013，19（33）：5430-5438.
［173］ Marinova M，Rauch M，Mücke M，et al.High-intensity focused ultrasound（HIFU）for pancreatic carcinoma：evaluation of feasibility，reduction of tumour volume and pain intensity［J］.Eur Radiol，2016，26（11）：4047-4056.
［174］ Kawamoto S，Permpongkosol S，Bluemke DA，et al.Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms：role of CT and MR imaging［J］.Radiographics，2007，27（2）：343-355.
［175］ Henzler T，Shi J，Jafarov H，et al.Functional CT imaging techniques for the assessment of angiogenesis in lung cancer［J］.Transl Lung Cancer Res，2012，1（1）：78-83.
［176］ Bernhard J，Dietrich D，Glimelius B，et al.Clinical benefit response in pancreatic cancer trials revisited［J］.Oncol Res Treat，2014，37（1）：42-48.
［177］ Giardino A，Girelli R，Frigerio I，et al.Triple approach strategy for patients with locally advanced pancreatic carcinoma［J］.HPB，2013，15（8）：623-627.
［178］ Spiliotis JD，Datsis AC，Michalopoulos NV，et al.Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas［J］.Langenbecks Arch Surg，2007，392（1）：55-60.
［179］ Kallis Y，Phillips N，Steel A，et al.Analysis of endoscopic radiofrequency ablation of biliary malignant strictures in pancreatic cancer suggests potential survival benefit［J］.Dig Dis Sci，2015，60（11）：3449-3455.
［180］ Zou YP，Li WM，Zheng F，et al.Intraoperative radiofrequency ablation combined with 125iodine seed implantation for unresectable pancreatic cancer［J］.World J Gastroenterol，2010，16（40）：5104-5110.
［181］ Niu L，He L，Zhou L，et al.Percutaneous ultrasonography and computed tomography guided pancreatic cryoablation：feasibility and safety assessment［J］.Cryobiology，2012，65（3）：301-307.
［182］ Xu KC，Niu LZ，Hu YZ，et al.A pilot study on combination of cryosurgery and（125）iodine seed implantation for treatment of locally advanced pancreatic cancer［J］.World J Gastroenterol，2008，14（10）：1603-1611.
［183］ 牛立志，李海波，文卫锋.经皮冷消融治疗局部进展性胰腺癌的可行性［J］.中华胰腺病杂志，2011，11（1）：1-4.
［184］ 牛立志，何丽华，周亮.经皮冷消融与125I粒子置入联合化疗治疗67例晚期胰腺癌的疗效和安全性［J］.中华肿瘤杂志，2012，34（1）：940-944.
［185］ Chen JB，Li JL，He LH，et al.Radical treatment of stageⅣpancreatic cancer by the combination of cryosurgery and iodine-125seed implantation［J］.World J Gastroenterol，2012，18（47）：7056-7062.
［186］ Niu L，Chen J，He L，et al.Combination treatment with comprehensive cryoablation and immunotherapy in metastatic pancreatic cancer［J］.Pancreas，2013，42（7）：1143-1149.
［187］ Narayanan G，Hosein PJ，Beulaygue IC，et al.Percutaneous image-guided irreversible electroporation for the treatment of unresectable，locally advanced pancreatic adenocarcinoma［J］.J Vasc Interv Radiol，2017，28（3）：342-348.
［188］ Mansson C，Brahmstaedt R，Nilsson A，et al.Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy［J］.Eur J Surg Oncol，2016，42（9）：1401-1406.
［189］ Paiella S，Butturini G，Frigerio I，et al.Safety and feasibility of Irreversible Electroporation（IRE）in patients with locally advanced pancreatic cancer：results of a prospective study［J］.Dig Surg，2015，32（2）：90-97.
［190］ Belfiore MP，Ronza FM，Romano F，et al.Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer：our preliminary experience［J］.Int J Surg，2015，21（Suppl 1）：S34-S39.
［191］ Martin RC 2nd，Kwon D，Chalikonda S，et al.Treatment of 200locally advanced（stageⅢ）pancreatic adenocarcinoma patients with irreversible electroporation：safety and efficacy［J］.Ann Surg，2015，262（3）：486-494.
［192］ Kluger MD，Epelboym I，Schrope BA，et al.Single-institution experience with irreversible electroporation for T4pancreatic cancer：first 50patients［J］.Ann Surg Oncol，2016，23（5）：1736-1743.
［193］ Lambert L，Horejs J，Krska Z，et al.Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation：general hospital cancer center experience［J］.Neoplasma，2016，63（2）：269-273.
［194］ Yan L，Chen YL，Su M，et al.A single-institution experience with open irreversible electroporation for locally advanced pancreatic carcinoma［J］.Chin Med J，2016，129（24）：2920-2925.
［195］ Zhang Y，Shi J，Zeng J，et al.Percutaneous irreversible electroporation for ablation of locally advanced pancreatic cancer：experience from a Chinese institution［J］.Pancreas，2017，46（2）：e12-e14.
［196］ Scheffer HJ，Vroomen LG，de Jong MC，et al.Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation：results of the PhaseⅠ／ⅡPANFIRE study［J］.Radiology，2017，282（1）：585-597.
［197］ Carrafiello G，Ierardi AM，Fontana F.Microwave ablation of pancreatic head cancer：safety and efficacy［J］.J Vasc Interv Radiol，2013，24（10）：1513-1520.
［198］ Zhao J，Zhao F，Shi Y，et al.The efficacy of a new high intensity focused ultrasound therapy for locally advanced pancreatic cancer［J］.J Cancer Res Clin Oncol，2017，143（10）：2105-2111.
［199］ Ning ZY，Cheng CS，Xie J，et al.A retrospective analysis of survival factors of high intensity focused ultrasound（HIFU）treatment for unresectable pancreatic cancer［J］.Discov Med，2016，21（118）：435-445.
［200］ Li X，Wang K，Zheng L，et al.Retrospective analysis of high intensity focused ultrasound combined with S-1in the treatment of metastatic pancreatic cancer after failure of gemcitabine［J］.Am J Cancer Res，2015，6（1）：84-90.
［201］ Li YJ，Huang GL，Sun XL，et al.The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma［J］.World J Surg Oncol，2016，14（1）：60.
［202］ Vidal-Jove J，Perich E，del Castillo MA.Ultrasound Guided High Intensity Focused Ultrasound for malignant tumors：the spanish experience of survival advantage in stageⅢandⅣpancreatic cancer［J］.Ultrason Sonochem，2015，27（1）：703-706.
［203］ Gao HF，Wang K，Meng ZQ，et al.High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer［J］.Hepatogastroenterology，2013，60（128）：1906-1910.
［204］ Li PZ，Zhu SH，He W，et al.High-intensity focused ultrasound treatment for patients with unresectable pancreatic cancer［J］.Hepatobiliary Pancreat Dis Int，2012，11（1）：655-660.
［205］ Sung HY，Jung SE，Cho SH，et al.Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer［J］.Pancreas，2011，40（7）：1080-1086.
［206］ Zhao H，Yang G，Wang D，et al.Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer［J］.Anticancer Drugs，2010，21（4）：447-452.